Docetaxel

Generic Name
Docetaxel
Brand Names
Taxotere, Docetaxel Accord, Docetaxel Kabi
Drug Type
Small Molecule
Chemical Formula
C43H53NO14
CAS Number
114977-28-5
Unique Ingredient Identifier
699121PHCA
Background

Docetaxel is a clinically well established anti-mitotic chemotherapy medication used for the treatment of different types of cancer, including breast, ovarian, and non-small cell lung cancer. Docetaxel is a complex diterpenoid molecule and a semisynthetic analogue of paclitaxel. Docetaxel reversibly binds to microtubulin with high affinity in a 1:1 stoichiom...

Indication

Docetaxel is indicated as a single agent for the treatment of locally advanced or metastatic breast cancer after chemotherapy failure; and with doxorubicin and cyclophosphamide as adjuvant treatment of operable node-positive BC. It is also indicated as a single agent for locally advanced or metastatic non-small cell lung cancer (NSCLC) after platinum therapy...

Associated Conditions
Esophageal Cancer, Ewing's Sarcoma, Locally Advanced Breast Cancer (LABC), Metastatic Bladder Cancer, Metastatic Breast Cancer, Metastatic Squamous Cell Carcinoma of the Head and Neck (HNSCC), Node Positive Breast Cancer, Ovarian Cancer Metastatic, Small Cell Lung Cancer (SCLC), Soft Tissue Sarcoma, Advanced untreated gastric adenocarcinoma, Locally advanced Squamous cell carcinoma of head and neck, Locally advanced untreated non small cell lung cancer, Metastatic untreated non small cell lung cancer, Refractory, locally advanced Non small cell lung cancer, Refractory, metastatic Non small cell lung cancer, Refractory, metastatic hormone-refractory Prostate cancer
Associated Therapies
-
Clinical Trials
Related News

Trial Studying Chemotherapy in Nigerian Women With Triple Negative Breast Cancer

First Posted Date
2024-03-04
Last Posted Date
2024-08-16
Lead Sponsor
University of Chicago
Target Recruit Count
85
Registration Number
NCT06291064

Treatment of High-Risk Prostate Cancer Guided by Novel Diagnostic Radio- and Molecular Tracers

First Posted Date
2024-02-28
Last Posted Date
2024-02-28
Lead Sponsor
Cancer Research Antwerp
Target Recruit Count
493
Registration Number
NCT06282588
Locations
🇧🇪

AZ Groeninge, Kortrijk, Belgium

🇧🇪

GZA Sint-Augustinus, Wilrijk, Antwerp, Belgium

🇧🇪

OLVZ Aalst, Aalst, Belgium

and more 8 locations

A Study of KK2269 in Adult Participants With Solid Tumors

First Posted Date
2024-02-20
Last Posted Date
2024-04-26
Lead Sponsor
Kyowa Kirin, Inc.
Target Recruit Count
71
Registration Number
NCT06266299
Locations
🇯🇵

National Cancer Center Hospital, Chuo-ku, Tokyo, Japan

🇯🇵

National Cancer Center Hospital East, Kashiwa City, Chiba, Japan

FT825/ONO-8250, an Off-the-Shelf, HER2 CAR-T, With or Without Monoclonal Antibodies in Advanced Solid Tumors

First Posted Date
2024-02-05
Last Posted Date
2024-08-23
Lead Sponsor
Fate Therapeutics
Target Recruit Count
351
Registration Number
NCT06241456
Locations
🇺🇸

Icahn School of Medicine at Mount Sinai, New York, New York, United States

🇺🇸

Ohio State University - Comprehensive Cancer Center, Columbus, Ohio, United States

🇺🇸

Yale New Haven Hospital - Yale Cancer Center, New Haven, Connecticut, United States

and more 8 locations

A Prospective, Open, Multicenter Single-arm Clinical Studie of Docetaxel, Carboplatin Combined With Inetetamab and Pyrotinib in the Treatment of Local-advanced HER2-positive Breast Cancer

First Posted Date
2024-01-31
Last Posted Date
2024-01-31
Lead Sponsor
Wang Ouchen
Target Recruit Count
154
Registration Number
NCT06234137
Locations
🇨🇳

the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China

Precise Neoadjuvant Chemoresection of Low Grade NMIBC

First Posted Date
2024-01-26
Last Posted Date
2024-01-26
Lead Sponsor
University of Bern
Target Recruit Count
28
Registration Number
NCT06227065
Locations
🇨🇭

Roland Seiler, Biel, Switzerland

Phase II Trial of Neoadjuvant Chemotherapy (NAC) Alone or in Combination With Immunotherapy Vaccine PRGN-2009 in Subjects With Newly Diagnosed HPV-Associated Oropharyngeal (Head and Neck) Cancer

First Posted Date
2024-01-25
Last Posted Date
2024-12-06
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
70
Registration Number
NCT06223568
Locations
🇺🇸

National Institutes of Health Clinical Center, Bethesda, Maryland, United States

A Study of KC1036 Versus Investigator's Choice of Chemotherapy in Patients With Advanced Esophageal Cancer

First Posted Date
2024-01-08
Last Posted Date
2024-03-07
Lead Sponsor
Beijing Konruns Pharmaceutical Co., Ltd.
Target Recruit Count
490
Registration Number
NCT06194734
Locations
🇨🇳

Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, China

A Study Comparing BL-B01D1 With Physician's Choice of Chemotherapy in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma

First Posted Date
2023-11-07
Last Posted Date
2024-07-18
Lead Sponsor
Sichuan Baili Pharmaceutical Co., Ltd.
Target Recruit Count
368
Registration Number
NCT06118333
Locations
🇨🇳

Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China

A Study of AB801 Monotherapy and Combination Therapy in Participants With Advanced Malignancies

Phase 1
Recruiting
Conditions
Advanced Cancer
Interventions
Drug: AB801
Drug: Zimberelimab
Drug: Docetaxel
First Posted Date
2023-11-07
Last Posted Date
2024-12-20
Lead Sponsor
Arcus Biosciences, Inc.
Target Recruit Count
80
Registration Number
NCT06120075
Locations
🇺🇸

START Midwest, Grand Rapids, Michigan, United States

🇺🇸

Sarah Cannon Research Institute, Denver, Colorado, United States

🇺🇸

Georgtown, Washington, District of Columbia, United States

and more 7 locations
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy